Company intelligence / Profile preview

Medical Harbour

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Harbour BioMed has advanced over 19 molecules into the IND stage through internal and partner-led programs, with clinical-stage assets in immunology and oncology. Pipeline highlights include batoclimab (HBM9161) in autoimmune diseases (Phase 2/3 ex-China) and porustobart (HBM4003) in oncology (Phase 1/2), as well as multiple assets in preclinical development[4][2][1].

Therapeutic areas: ImmunologyMetabolic DisordersOncology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateProteinSmall molecule
Industry: Biotech

Partnerships

AbbVie (global license agreement)[3]Multiple undisclosed pharmaceutical and biotech co-development and licensing partners[4][1]

Beyond the preview

Go deeper on Medical Harbour.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medical Harbour.

Explore the full profile